Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.46 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.46 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 3/20 | 0.42 |
| ▸ | RXRB | P28702 | 3/20 | 0.42 |
| ▸ | RXRG | P48443 | 3/20 | 0.42 |
| ▸ | RARB | P10826 | 2/20 | 0.42 |
| ▸ | RARG | P13631 | 2/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 4/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28045873 | 0.82 | HCAR2 (0.52) | HCAR2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL16742919 | 0.81 | FFAR2 (0.45) | HCAR2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL9642942 | 0.74 | — | — | |
| SCHEMBL2412676 | 0.73 | ALDH1A1 (0.55) | HCAR2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL15321067 | 0.73 | CDC7 (0.55) | KDM4EALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL1810308 | 0.73 | HCAR2 (0.61) | HCAR2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL16198634 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL11597191 | 0.71 | HCAR2 (0.59) | HCAR2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL324369 | 0.71 | — | — | |
| SCHEMBL16995339 | 0.71 | HCAR2 (0.48) | HCAR2FFAR2KDM4EALDH1A1PFKFB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077380-B1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI SA (FR) | 2018-07-25 | — | — | EP | disclosed |
| US-9776991-B2 | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | SANOFI (FR) | 2017-10-03 | — | — | US | disclosed |
| US-20160326146-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI (FR) | 2016-11-10 | — | — | US | disclosed |
| EP-3077380-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | Sanofi (FR) | 2016-10-12 | — | — | EP | disclosed |
| US-9227951-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227951-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| WO-2015082474-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI (FR) | 2015-06-11 | — | — | WO | disclosed |
| EP-2881390-A1 | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | SANOFI (FR) | 2015-06-10 | — | — | EP | disclosed |
| US-20140228416-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228416-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8546588-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011106627-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106627-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-7189851-B2 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2003076440-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | CALCRL, CALCR, CALCB | HCAR2 56/4885PRKAB2 2247/4885PRKAG1 1558/4885 |
| US-20160326146-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, LTA4H | HCAR2 273/4885PRKAB2 3718/4885PRKAG1 3961/4885 |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | HCAR2 24/4885PRKAB2 3662/4885PRKAG1 4065/4885 |
| US-20140228416-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | HCAR2 24/4885PRKAB2 3662/4885PRKAG1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.